Global Hematology Partnering Deal Trends, Players and Financials 2014-2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Hematology Partnering 2014-2019: Deal trends, players and financials”
report has been added to ResearchAndMarkets.com’s
offering.

Global Hematology Partnering 2014 to 2019 provides the full collection
of Hematology disease deals signed between the world’s pharmaceutical
and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee
obtains a right or an option right to license a licensor’s product or
technology. More often these days these deals tend to be multi-component
including both a collaborative R&D and a commercialization of outcomes
element.

The report takes readers through the comprehensive Hematology disease
deal trends, key players and top deal values allowing the understanding
of how, why and under what terms companies are currently entering
Hematology deals.

The report presents financial deal terms values for Hematology deals,
where available listing by overall headline values, upfront payments,
milestones and royalties enabling readers to analyse and benchmark the
value of current deals.

In addition, a comprehensive appendix is provided with each report of
all Hematology partnering deals signed and announced since 2014. The
appendices are organized by company A-Z, stage of development at
signing, deal type (collaborative R&D, co-promotion, licensing etc) and
technology type. Each deal title links via Weblink to an online version
of the deal record and where available, the contract document, providing
easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the
trends and activities in Hematology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Hematology technologies and products.

Report scope

Global Hematology Partnering 2014 to 2019 includes:

• Trends in Hematology dealmaking in the biopharma industry since 2014
• Analysis of Hematology deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Hematology deal contract documents
• Comprehensive access to over 190 Hematology deal records
• The leading Hematology deals by value since 2014
• Most active Hematology dealmakers since 2014

The report includes deals for the following indications:
Agranulocytosis, Anemia, Haemolytic, Iron deficiency, Blood substitute,
Disseminated intravascular coagulation (DIC), Hemophilia, Immune
thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia,
Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus
other hematological indications.

Available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or
  deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Hematology dealmaking

2.1. Introduction

2.2. Hematology partnering over the years

2.3. Hematology partnering by deal type

2.4. Hematology partnering by industry sector

2.5. Hematology partnering by stage of development

2.6. Hematology partnering by technology type

2.7. Hematology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Hematology partnering

3.1. Introduction

3.2. Disclosed financials terms for Hematology partnering

3.3. Hematology partnering headline values

3.4. Hematology deal upfront payments

3.5. Hematology deal milestone payments

3.6. Hematology royalty rates

Chapter 4 – Leading Hematology deals and dealmakers

4.1. Introduction

4.2. Most active in Hematology partnering

4.3. List of most active dealmakers in Hematology

4.4. Top Hematology deals by value

Chapter 5 – Hematology contract document directory

5.1. Introduction

5.2. Hematology partnering deals where contract document available

Chapter 6 – Hematology dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Hematology therapeutic target

Appendices

Appendix 1 – Directory of Hematology deals by company A-Z 2014 to 2019

Appendix 2 – Directory of Hematology deals by deal type 2014 to 2019

Appendix 3 – Directory of Hematology deals by stage of development 2014
to 2019

Appendix 4 – Directory of Hematology deals by technology type 2014 to
2019

For more information about this report visit https://www.researchandmarkets.com/r/kdetkk

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs